Finding new osteoarthritis medicines via AI and genetics
Researchers are using AI-driven molecular biology and genetic data from Utah families to identify new drug candidates for osteoarthritis. By targeting the WNK2 gene, the team aims to develop treatments that address the disease's root cause rather than just managing symptoms.
Why it matters
Demonstrates the potential for AI to drastically accelerate drug discovery and provide new therapeutic options for chronic, debilitating conditions.
edited by Gaby Clark , reviewed by Robert Egan
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add as preferred source Credit: Unsplash/CC0 Public Domain Osteoarthritis (OA) is a chronic, painful joint disease and a leading cause of disability. Despite its prevalence, therapies for osteoarthritis are limited and focus on symptom management. Now, researchers are combining genetic studies of Utah families with AI-based molecular biology tools to find new medications that may ultimately help treat OA at its source.
One such new drug appears to promote joint health and reduce inflammation-related genes in a model of osteoarthritis based on cells in a dish. While it has yet to be tested for safety and efficacy in a living organism, the new compound provides a starting point for innovative OA therapies.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in